Revolutionary Systemic Care
The human body's largest organ - skin - greatly benefits from NanoMD® novel 3-way impact.
NanoMD® is a nano-particle drug in a tablet form to naturally reverse pigmentation and UV damage.
NanoMD® was developed by a multi-disciplinary team of world-class researchers. It utilizes nanotechnologies that radically improve the bioavailability of chemical compounds used in pharmaceuticals & nutraceuticals.
Beside its unique de-pigmenting and sun protecting action, NanoMD® was clinically proven to support the overall condition of blood vessels. They remain supple and flexible which allows for nutrients to reach the organs keeping them healthy.
What is NanoMD® BRIT-N™?
The NanoMD® is the world's most advanced supplement for skin protection, nutrition and brightening. It represents the cutting-edge scientific discovery in nutrition and nano technology in a one-tablet-a-day form.
HOw does it work and WHAT DOES IT DO?
The NanoMD® unique formula of patented and clinically proven ingredients and custom designed nano technology that radically increases its bioavailability makes it the most powerful supplement that is able to add years of healthy, glowing skin.
Clinical Trials
NanoMD® was developed by a multi-disciplinary team of world-class researchers and developers. It utilizes nanotechnologies that radically improve the bioavailability of chemical compounds used in pharmaceuticals & nutraceuticals. NanoMD® contains patented ingredients. Use of the product is protected by one or more U.S. and other international patents.
Novel Supplement with Phenolic Compounds for Treatment of Melasma: Double Blind Placebo Controlled Trial Safety and Efficacy Evaluation, Corresponding Author: Downie, J. B., MD, FAAD, Image Dermatology, Montclair, NJ, USA; Journal: Dermatology and Dermatologic Diseases, 5(1).; Copyright: © 2018 Downie J, et al.
Background: Melasma is a chronic skin problem that causes dark, discolored patches on the skin and therefore can have adverse effects on quality of life. Recently, a novel complex was shown to decrease melasma. Specifically, the goal of the study was to prove that the formula can reduce melasma, overall hyperpigmentation and nontransient erythema.
Methods: Forty subjects with Fitzpatrick skin types III-V were enrolled in the double-blinded, randomized, placebo controlled trial: 20 were treated over 90 days with the oral supplement and 20 received a placebo over 90 days. Subjects were assessed at onset and re-assessed at 60 and 90 days by the Modified Melasma Area and Severity Index (mMASI), photographic documentation, hyperpigmentation tool, erythema index and client satisfaction. Subjects used the product or a placebo (in tablet form) orally once a day.
Conclusion: Consistent, statistically significant reductions in melasma, as measured by mMASI scores, overall hyperpigmentation and non-transient erythema scores were achieved while meeting patient expectations at the 90 day follow-up evaluation point when compared to placebo. Results from this clinical trial suggest that this oral supplement is an effective treatment for melasma and may provide an alternative treatment for overall hyperpigmentation and non-transient erythema, while meeting expectations of patients. The product was well tolerated, with no reports of adverse events or side effects.
Patient Satisfaction
Patients were surveyed, whether they would recommend treatment to a friend. Satisfaction values were collected. 80% of surveyed patients report they would recommend the treatment to a friend.
Satisfaction Values [%]
References
1. Downie, J. B., Abdullah, N. A. (2018). Novel Supplement with Phenolic Compounds for Treatment of Melasma: Double Blind Placebo Controlled Trial Safety and Efficacy Evaluation. Dermatology and Dermatologic Diseases, 5(1).
2. Aust O, Stahl W, Sies H, Tronnier H, Heinrich U (2005) Supplementation with tomato-based products increases lycopene, phytofluene, and phytoene levels in human serum and protects against UV-light-induced erythema. Int J Vitam Nutr Res 75: 54-60.
3. Saliou C, Rimbach G, Moini H, et al. Solar ultraviolet-induced erythema in human skin and nuclear factor-kappa-B-dependent gene expression in keratinocytes are modulated by a French maritime pine bark extract. Free Radic Biol Med. 2001;30(2):154-160.
4. Ni, Z., Mu, Y., & Gulati, O. (2002). Treatment of melasma with Pycnogenol®. Phytotherapy Research, 16(6), 567-571.
5. Maritime Pine Extract. The United States Pharmacopoeia 31/The National Formulary 26. Vol 1. Rockville, MD: The US Pharmacopoeial Convention; 2008:977-978.
6. Wei ZH, Peng QL, Lau BHS. Pycnogenol enhances endothelial cell antioxidant defenses. Redox Rep. 1997;3(4):219-224.
7. Sarikaki V, Rallis M, Tanojo H. In vitro percutaneous absorption of pine bark (Pycnogenol) in human skin. J Tox Cutaneous Ocular Tox. 2004;23(3):149-158.
8. Grimm T, Skrabala R, Chovanova Z, et al. Single and multiple dose pharmacokinetics of maritime pine bark extract (pycnogenol) after oral administration to healthy volunteers. BMC Clin Pharmacol. 2006b;6:4.
9. Cossins E, Lee R, Packer L. ESR studies of vitamin C regeneration, order of reactivity of natural source phytochemical preparations. Biochem Mol Biol Int. 1998;45(3):583-597.
10. Blazso G, Gabor M, Rohdewald P. Anti-inflammatory activities of procyanidincontaining extracts from Pinus pinaster Ait. after oral and cutaneous application. Pharmazie. 1997;52(5):380-382.